The well-worn adage “good companies are bought, not sold” suggests that top-tier businesses, especially in high-growth industries like life sciences, do not need to seek buyers; instead, buyers pursue them. While some high-profile examples grab headlines, they are the exception, not the norm — especially in life sciences. As specialists in life science transactions, we advise management and boards to challenge this myth. Believing “good companies are bought, not sold” can be dangerously misleading and does not reflect the reality of the overwhelming majority of acquisitions in this sector.
Outcome Capital has been named Life Sciences Review’s exclusive recipient of the “Top Life Sciences Advisory and Strategic Investment Banking Solutions 2026” award, recognizing its unique approach to helping life sciences companies move innovations from development to commercialization. The firm combines scientific, clinical, operational, and financial expertise to support emerging and growth-stage companies with fundraising, […]
Read More
Outcome Capital Life Science Market Pulse June 2026 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?